MENU

Speakers


  • Burkhard Becher, PhD
    Burkhard Becher, PhD

    Professor and Chairman, Institute of Experimental Immunology, University of Zurich

    BIOGRAPHY
  • Richard Head, MS
    Richard Head, MS

    Director, Genome Technology Access Center, McDonnell Genome Institute, Washington University School of Medicine, St. Louis

    BIOGRAPHY
  • David King, PhD
    David King, PhD

    Senior Vice President, Head of R&D Genomics, Standard BioTools

    BIOGRAPHY
  • Hema Kothari, PhD
    Hema Kothari, PhD

    Assistant Professor, Department of Medicine, Cardiovascular Medicine Division, University of Virginia

    BIOGRAPHY
  • Noel de Miranda, PhD
    Noel de Miranda, PhD

    Principal Investigator, Leiden University Medical Center

    BIOGRAPHY
  • Evan Newell, PhD
    Evan Newell, PhD

    Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center

    BIOGRAPHY
  • Hiroyoshi Nishikawa, MD, PhD
    Hiroyoshi Nishikawa, MD, PhD

    Professor, National Cancer Center, Japan

    BIOGRAPHY
  • David Novo, Phd
    David Novo, Phd

    President, De Novo Software

    BIOGRAPHY
  • Patrick Reeves, PhD
    Patrick Reeves, PhD

    Instructor in Medicine, Massachusetts General Hospital

    BIOGRAPHY
  • Kurt Schalper, MD, PhD
    Kurt Schalper, MD, PhD

    Assistant Professor of Pathology, Director, Translational Immuno-Oncology Laboratory, Yale School of Medicine

    BIOGRAPHY
JUL 7, 2020 Opens: 6:00 AM - 12:00 PM PT

Fluidigm Infectious Disease and Oncology Virtual Summit

Fluidigm technologies are integral to supporting current progress in cancer, immunology and infectious disease research. Fluidigm has also developed new tools for SARS-CoV-2 detection and diagnostics.

You’ll hear from our lineup of exceptional speakers on their latest findings in infectious disease, oncology or immuno-oncology research. Scroll down to see the speakers.

During this half-day virtual event from 6:00am -12:00pm PT we invite you to:

  • Hear about new exciting instrument and reagent products in booths and from product introduction sessions in meeting rooms.

  • Visit booths to watch a video, browse publication highlights, access resources and chat with us to learn how Fluidigm mass cytometry, microfluidics and laser capture detection technologies and services provide unique solutions to difficult research problems.

  • Discover our high-throughput microfluidics-based solutions for viral detection including the Advanta™ DX SARS-CoV-2 RT-PCR Assay, our new extraction-free saliva-based EUA IVD for SARS‑CoV‑2.

  • Join us for the unveiling of a new Fluidigm product—an automated sample preparation system specifically designed to improve flow and mass cytometry workflows.

  • Learn about the novel AccuLift™ Laser Capture Microdissection System, which enables researchers to capture regions or single cells within the tumor microenvironment for spatial biology insights and to unlock unique molecular signatures.

In the current pandemic, Fluidigm is here to help in every way we can to make meaningful advances in the fight against COVID-19. Learn more about our COVID-19 research and detection solutions at this insightful event, including the June 12 announcement of our Emergency Use Authorization (EUA) filing with the U.S. Food and Drug Administration (FDA) for an extraction-free saliva-based test for high-throughput detection of the SARS‑CoV‑2 virus.

We look forward to meeting you!

 

For Research Use Only. Not for use in diagnostic procedures.

Fluidigm has filed for Emergency Use Authorization with the FDA. The test has been validated by Fluidigm, but the FDA’s independent review of this validation is pending.

The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is a real-time RT-PCR test intended for the qualitative detection of RNA from the SARS-CoV-2 in saliva specimens from individuals suspected of COVID-19 by their health care provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high-complexity tests, or by similarly qualified non-U.S. laboratories.

The Advanta Dx SARS-CoV-2 RT-PCR Assay is the subject of an EUA filing with the FDA. The FDA may require additional data, validation and/or testing, and may not ultimately provide authorization. An EUA, if granted, does not constitute FDA clearance or approval, but would allow use by authorized laboratories only while the EUA is in effect.

Information in this publication is subject to change without notice. Patent and license information: fluidigm.com/legal/notices. Trademarks: Fluidigm, the Fluidigm logo, AccuLift and Advanta are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. ©2020 Fluidigm Corporation. All rights reserved. 06/2020


Speakers
  • Burkhard Becher, PhD

    Professor and Chairman, Institute of Experimental Immunology, University of Zurich
    BIOGRAPHY
  • Richard Head, MS

    Director, Genome Technology Access Center, McDonnell Genome Institute, Washington University School of Medicine, St. Louis
    BIOGRAPHY
  • David King, PhD

    Senior Vice President, Head of R&D Genomics, Standard BioTools
    BIOGRAPHY
  • Hema Kothari, PhD

    Assistant Professor, Department of Medicine, Cardiovascular Medicine Division, University of Virginia
    BIOGRAPHY
  • Noel de Miranda, PhD

    Principal Investigator, Leiden University Medical Center
    BIOGRAPHY
  • Evan Newell, PhD

    Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
    BIOGRAPHY
  • Hiroyoshi Nishikawa, MD, PhD

    Professor, National Cancer Center, Japan
    BIOGRAPHY
  • David Novo, Phd

    President, De Novo Software
    BIOGRAPHY
  • Patrick Reeves, PhD

    Instructor in Medicine, Massachusetts General Hospital
    BIOGRAPHY
  • Kurt Schalper, MD, PhD

    Assistant Professor of Pathology, Director, Translational Immuno-Oncology Laboratory, Yale School of Medicine
    BIOGRAPHY

Show Resources
You May Also Like
OCT 19, 2022 5:30 AM PDT
C.E. CREDITS
OCT 19, 2022 5:30 AM PDT
Labroots announces the 2022 Coronavirus Virtual Event Series. A novel coronavirus emerged in China in 2019; it has since been dubbed COVID-19....
NOV 09, 2022 6:00 AM PST
NOV 09, 2022 6:00 AM PST
Labroots is pleased to host the annual 2022 Clinical Diagnostics and Research virtual event to be held on November 9th, 2022. Registration is open now....
NOV 09, 2023 6:00 AM PST
NOV 09, 2023 6:00 AM PST
Labroots is pleased to announce the 2023 Clinical Diagnostics and Research Virtual Event to be held on November 9th, 2023 packed with featured speakers....
SEP 05, 2023 6:00 AM PDT
SEP 05, 2023 6:00 AM PDT
Labroots to host the Microbiology Virtual Week on September 5-7, 2023. Offering discussions on the global development of treatment for Infectious Diseases....
OCT 04, 2022 5:30 AM PDT
C.E. CREDITS
OCT 04, 2022 5:30 AM PDT
Labroots to host the 10th Annual Cancer Research and Immuno-oncology Virtual Event! This two day event will take place on October 4-6, 2022....
APR 20, 2023 6:00 AM PDT
APR 20, 2023 6:00 AM PDT
Labroots is pleased to host the 6th 2023 Cannabis Sciences Virtual Event. Labroots will host the event on April 20 2023, filled with featured speakers....

Agenda

  • JUL 07, 2020 11:00 AM PDT

    Comprehensive landscape of the tumor microenvironment analyzed with CyTOF® technology

    Hiroyoshi Nishikawa, MD, PhD
    Professor, National Cancer Center, Japan
    BIOGRAPHY
  • JUL 07, 2020 10:30 AM PDT

    Identification of human immune cell subtypes most vulnerable to IL-1β-induced inflammatory signaling using mass cytometry

    Hema Kothari, PhD
    Assistant Professor, Department of Medicine, Cardiovascular Medicine Division, University of Virginia
    BIOGRAPHY
  • JUL 07, 2020 10:00 AM PDT

    Visualization and Analysis of High-Parameter CyTOF® Data with FCS Express in Record Time

    David Novo, Phd
    President, De Novo Software
    BIOGRAPHY
  • JUL 07, 2020 9:30 AM PDT

    Evaluating tumor-immune cell interactions in human lung cancer using multiparametric and spatially resolved tissue analysis

    Kurt Schalper, MD, PhD
    Assistant Professor of Pathology, Director, Translational Immuno-Oncology Laboratory, Yale School of Medicine
    BIOGRAPHY
  • JUL 07, 2020 9:00 AM PDT

    Mass cytometry in vaccine development: utility and considerations

    Patrick Reeves, PhD
    Instructor in Medicine, Massachusetts General Hospital
    BIOGRAPHY
  • JUL 07, 2020 8:00 AM PDT

    Development of an extraction-free, saliva-based workflow for SARS-CoV-2 detection with the Biomark™ HD platform

    David King, PhD, Richard Head, MS
    David King, PhD
    Senior Vice President, Head of R&D Genomics, Standard BioTools
    BIOGRAPHY
    Richard Head, MS
    Director, Genome Technology Access Center, McDonnell Genome Institute, Washington University School of Medicine, St. Louis
    BIOGRAPHY
  • JUL 07, 2020 7:30 AM PDT

    Deciphering T cell heterogeneity in humans through analysis of antigen-specificity

    Evan Newell, PhD
    Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
    BIOGRAPHY
  • JUL 07, 2020 6:30 AM PDT

    Deep immunophenotyping of cancer microenvironments by Imaging Mass Cytometry™

    Noel de Miranda, PhD
    Principal Investigator, Leiden University Medical Center
    BIOGRAPHY
  • JUL 07, 2020 6:00 AM PDT

    Single-cell mapping of human brain cancer reveals tumor-driven education of tumor-associated leukocytes

    Burkhard Becher, PhD
    Professor and Chairman, Institute of Experimental Immunology, University of Zurich
    BIOGRAPHY
Meeting Room Agenda

Time (PT)

Speaker

Title

Institution

Talk Title

6:006:30

Nick Jordan

Field Applications Specialist, Genomics

Fluidigm

Detection and characterization of viral pathogens with microfluidics-based genomic analysis

6:30‒7:00

Jordan Moore

Senior Field Applications Manager, Genomics

 

Fluidigm

Advanta™ Dx SARS-CoV-2 RT-PCR Assay for high-throughput COVID-19 diagnostic testing with saliva for use with FDA EUA

 

7:00‒7:30

Noah Saederup, PhD

Senior Product Manager, Maxpar Reagents

Fluidigm

Easy, flexible and comprehensive:
the Maxpar® Direct™ family of immune profiling assays

7:30‒8:00

Shariq Mujib, PhD

 

Thiru Selvanantham, PhD

Product Development Scientist

Product Manager, Mass Cytometry

Fluidigm

Expanding the Maxpar® Direct Immune Profiling Assay™ from 30 to 44 markers

8:00‒8:30

Alan Carpino

Director, LCM Business Development

Fluidigm

Capture Down to a Single Cell – AccuLift Laser Capture Microdissection Portfolio

8:30‒9:00

Teri Oldaker, BS

Michelle Poulin, PhD

 

Principle Consultant

Senior Manager, Mass Cytometry Field Applications

Oldaker Consulting

Fluidigm

 

Sample preparation for flow cytometry: practical considerations.

Flow Conductor™: a sample preparation system for flow and mass cytometry

9:00–9:30

Steve Kain, PhD

Director, Product Management

Fluidigm

Detection of human and viral full-length RNA using a nanoscale microfluidic platform

9:30–10:00

Rusk Malladi, MS

Senior Marketing Manager, Microfluidics

Fluidigm

Advanta Dx SARS-CoV-2 RT-PCR Assay for high-throughput COVID-19 diagnostic testing with saliva for use with FDA EUA

10:00–10:30

Michelle Poulin, PhD

Senior Manager, Mass Cytometry Field Applications

Fluidigm

CyTOF for all: the top eight reasons to use mass cytometry for your project

10:30–11:00

Noah Saederup, PhD

Senior Product Manager

Fluidigm

Easy, flexible and comprehensive:
The Maxpar® Direct™ family of immune profiling assays

11:00–11:30

Alan Carpino

Director, LCM Business Development

Fluidigm

Capture Down to a Single Cell – AccuLift Laser Capture Microdissection Portfolio

11:30–12:00

Teri Oldaker, BS

Michelle Poulin, PhD

 

Principle Consultant

Senior Manager, Mass Cytometry Field Applications

Oldaker Consulting

Fluidigm

 

Sample preparation for flow cytometry: practical considerations.

Flow Conductor™: a sample preparation system for flow and mass cytometry

About Us

At Fluidigm, we empower our customers to reveal meaningful insights in health and disease, identify actionable markers to inform life decisions and accelerate the development of more effective therapies. Fluidigm develops, manufactures, and markets research products for life science analytical and preparatory systems for use in mass cytometry, high-throughput genomics, and single cell genomics applications. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide.

Help

Loading Comments...
Show Resources